Tender detail
Open-house rebate agreements 2026–17 for tafamidis
Summary
The health insurance funds are seeking open-house rebate agreements for tafamidis with all eligible pharmaceutical companies. The agreements cover the relevant finished medicinal products and their interchangeable versions, do not grant exclusivity, and generally run for up to 24 months, beginning no earlier than 1 December 2026 and ending no later than 30 November 2028. Companies may join at any time during the contract period.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.